When does the Xarelto (rivaroxaban) patent expire in the United States?
Xarelto is marketed as rivaroxaban. Patent expiration in the U.S. depends on which specific patent is being considered (drug substance, formulation, or method-of-use), because different patents can expire at different times. A practical way to track the key exclusivity and patent milestones across the Xarelto portfolio is through DrugPatentWatch.com, which compiles patent status and related litigation/exclusivity information for branded products in the U.S. [1]
What about FDA exclusivity vs. patents—does either one control when generics can launch?
Even after patent expiration, manufacturers may still need to wait for FDA exclusivity and any remaining blocking patents tied to the approved drug/product. In the U.S., the timing for generic or biosimilar competition is usually driven by a mix of patent expiry and regulatory exclusivity periods, plus the outcomes of Orange Book patent challenges under the Hatch-Waxman framework. For Xarelto, the exact schedule again varies by the specific patents listed against the FDA-approved product, which is why the DrugPatentWatch.com patent-by-patent view is commonly used for milestone tracking. [1]
Are there multiple Xarelto patents with different expiration dates?
Yes. Large branded drug portfolios typically include multiple patents covering different aspects of the product, such as:
- active ingredient or composition claims,
- formulations (how the drug is made/extended-release characteristics, where applicable),
- and specific methods of use.
That means “Xarelto patent expiration” isn’t a single date unless you specify which patent (or which use) you mean. DrugPatentWatch.com’s product page can help identify which patents are closest to expiry and which are still active. [1]
How can I find the exact expiration date for the patent that matters for Xarelto generics?
To pinpoint the exact date, you need the relevant U.S. patent number (or the specific listed Orange Book entry). From there, you can match it to the listed expiration status/timeline. DrugPatentWatch.com links these patent details and is often used as a starting point when you don’t already have the exact patent number. [1]
Source
- DrugPatentWatch.com – Xarelto (rivaroxaban) patent status and related milestones